TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07174310: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 900 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$3,305,760

Rescue Site Savings

+$2,203,840

Unlock Full NCT07174310 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07174310 Rescue Dossier →